Premium
1,25‐Dihydroxyvitamin D 3 ‐Differentiated Human Promyelocytic Leukaemia Cells (HL‐60) Can Kill Antibody‐Coated Tumour Cells (K562)
Author(s) -
ESPEVIK T.
Publication year - 1985
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/j.1365-3083.1985.tb01865.x
Subject(s) - k562 cells , antibody , cancer research , microbiology and biotechnology , immunology , leukemia , biology , chemistry
The active metabolite of vitamin D 3 1α,25‐dihydroxyvitamin D 3 , (1,25(OH) 3 D 3 ), was tested for the ability to differentiate promyelocytic leukaemia cells (HL‐60) and histocytic lymphoma cells (U937) into cytotoxic effector cells against K562 leukaemia cells. A concentration of 10 ‐6 M 1,25(OH) 2 D 3 differentiated HL‐60 cells into substrate‐adherent monoeyte‐like cell with cytolytic activity against antibody‐coated K562 cells. These differentiated HL‐60 cells were not able to lyse uncoated K562 cells in an 18‐h Cr‐release assay. Similar treatment of the U937 cells with l,25(OH) 2 D 3 did not make them cytolytic towards K562 cells. These data indicate that l,25(OH) 2 D 3 can differentiate HL‐60 cells to mature monocytes with cytolytic activity against antibody‐coated leukaemia cells.